Parabilis Medicines Inc (PBLS) FinancialsPBLSParabilis Medicines Inc

Evaluating the bottom line, Parabilis Medicines Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -34382.43%, while the net margin is -35447.97%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively PBLS converts its operational activities into shareholder value.

In the context of the broader market, PBLS competes directly with industry leaders such as ACAD and TARS. With a market capitalization of $3.20B, it holds a significant position in the sector. When comparing efficiency, PBLS's gross margin of 100.00% stands against ACAD's 90.81% and TARS's 93.03%. Such benchmarking helps identify whether Parabilis Medicines Inc is trading at a premium or discount relative to its financial performance.

Parabilis Medicines has shown a gross margin of 100% in Q2 2026, but has consistently reported negative net income, with losses of approximately $67 million in the same quarter. The company has no revenue in previous quarters, making its financial future uncertain.